

Press Release

# Genedata and Genmab Reach New Milestone in Digitalizing Translational and Clinical Research

*Industry-leading enterprise software for leveraging translational and clinical research simplifies data ingestion and access and extends analytical options for users*

**Basel, Switzerland – September 24, 2020** – Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the release of [Genedata Profiler® 15.0](#), the latest version of its enterprise software that makes translational and clinical research data more accessible, enabling scientists to make data-informed decisions through all stages of biopharma development. The latest release adds a highly intuitive portal that enables researchers and clinical scientists to find, access, and integrate the most relevant data for their specific application in a secure, high-performance, validation-ready environment.

Genedata Profiler 15.0 is the result of a development project in close collaboration between Genedata and Genmab, an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

“We have the brightest data scientists in the industry working on advancing our products through all stages of development with the goal of bringing effective therapies to patients as quickly as possible,” said Hisham Hamadeh, Ph.D., Vice President, Global Head of Data Sciences at Genmab. “The Genedata Profiler platform is used productively in a validated environment and is helping to democratize access to integrated data in the translational research and clinical settings.”

New features in Genedata Profiler include a new **Data Portal** with an interactive interface for secure self-service data access across all available studies and experiments, automated **Data Ingestion Workflows** with a wizard-like interface to load, structure, and quality-control data, and the improvement of **interoperability with third-party tools** to ingest, process, quality-control, and analyze data programmatically.

“We are excited about the success of our partnership with Genmab, a pioneer in the field of innovative biopharmaceuticals,” said Othmar Pfannes, Ph.D., CEO of Genedata. “The latest release of Genedata Profiler addresses key requirements of innovative biopharmaceutical R&D organizations. As the single source of truth for all translational and clinical research data, Genedata Profiler fuels innovation—a big step in biopharma digitalization. We look forward to expanding the Genedata Profiler platform over the next few years with our partners, to enable them to bring innovative biotherapeutics to the market even faster.”

## About Genedata

Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.

[www.genedata.com](http://www.genedata.com)

[LinkedIn](#) | [Twitter](#) | [YouTube](#)

---

**Contact**

Miles Fisher-Pollard  
Genedata  
Public Relations  
Phone: +41 61 511 85 61  
[pr@genedata.com](mailto:pr@genedata.com)

**Disclaimer**

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.